- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm…
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s…
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show…
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in…
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the…
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000…
Charlotte, North Carolina--(Newsfile Corp. - June 27, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one…
WESTFORD, Mass., June 27, 2024 /PRNewswire/ -- According to SkyQuest, the global IoT in Healthcare Market size was valued at USD…
NEW YORK, June 27, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life…
SEATTLE, June 27, 2024 /PRNewswire/ -- RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company providing advanced Precision Biology…